TransMedics Group, Inc. (TMDX) Gross Margin: 59.09%
Is TransMedics Group, Inc.’s gross margin high or low?
TransMedics Group, Inc.'s gross margin of 59.09% is in line with its 5-year average of 64.62%, near the low end of its 5-year range (59.09%–69.92%).
As of Saturday, June 20, 2026. 0.92% below its 12-month average of 59.64%.
TMDX Gross Margin Chart
TMDX Average Gross Margin Chart
TMDX Current vs Average Gross Margin Chart
TMDX Gross Margin Metrics
GROSS MARGIN
59.09%
GROSS MARGIN AVG TTM
59.64%
GROSS MARGIN AVG 3Y
63.22%
GROSS MARGIN AVG 5Y
64.62%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.92%
CURRENT VS 3Y AVG
-6.54%
CURRENT VS 5Y AVG
-8.55%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
TMDX Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TransMedics Group, Inc. (TMDX) | $2.72B | 59.09% | 59.64% | 63.22% | 64.62% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.07B | 48.93% | 50.81% | 52.12% | 52.25% |
| 23andMe Holding Co. (ME)vs › | $15.31M | 53.33% | 48.95% | 47.93% | 47.45% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.64B | 51.87% | 52.87% | 53.77% | 54.60% |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.91B | 67.64% | 76.65% | 78.21% | 76.94% |
| Tempus AI, Inc. (TEM)vs › | $8.87B | 69.55% | 62.30% | 54.75% | 44.45% |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.91B | 31.86% | 31.70% | 34.15% | 35.17% |
| Baxter International Inc. (BAX)vs › | $10.27B | 30.11% | 33.76% | 35.72% | 36.84% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 17.13% | 18.71% | 19.98% | 20.79% |
| Revvity, Inc. (RVTY)vs › | $11.16B | 51.44% | 50.55% | 50.58% | 52.43% |
Gross Margin Analysis
Gross Margin
59.1%
(Revenue - COGS) / Revenue
TransMedics Group, Inc. Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
TransMedics Group, Inc. Gross Margin FAQ
- What is the gross margin for TransMedics Group, Inc. (TMDX)?
- The gross margin for TMDX stock is 59.09%.
- Is TransMedics Group, Inc.'s gross margin high or low?
- TransMedics Group, Inc.'s gross margin of 59.09% is in line with its 5-year average of 64.62%, near the low end of its 5-year range (59.09%–69.92%).
- What is the TTM average gross margin for TransMedics Group, Inc. (TMDX)?
- The TTM average gross margin for TMDX stock is 59.64%.
- What is the 3Y average gross margin for TransMedics Group, Inc. (TMDX)?
- The 3Y average gross margin for TMDX stock is 63.22%.
- What is the 5Y average gross margin for TransMedics Group, Inc. (TMDX)?
- The 5Y average gross margin for TMDX stock is 64.62%.
TransMedics Group, Inc. Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2025-12-31 | 59.92% |
| 2024-12-31 | 59.36% |
| 2023-12-31 | 63.77% |
| 2022-12-31 | 69.84% |
| 2021-12-31 | 69.92% |
| 2020-12-31 | 64.88% |
| 2019-12-31 | 58.73% |
| 2018-12-31 | 44.05% |
| 2017-12-31 | 27.81% |
| 2016-12-31 | 12.34% |
Related Metrics
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein